SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH M impact

Nanobiotix Reports Phase 1 Response in Anti-PD-1-Resistant Melanoma

Nanobiotix announced a response in a Phase 1 study of melanoma resistant to anti-PD-1 treatment.

Related stories